Skip to main content
Top
Published in: Endocrine 2/2021

01-11-2021 | Cushing's Syndrome | Clinical Management of Endocrine Diseases

Rare complication of cushing’s syndrome in the elderly: a case report

Authors: Cui Li, Guihua Cao, Fengzhong Jin, Xiaoxuan Ning

Published in: Endocrine | Issue 2/2021

Login to get access

Abstract

Purpose

Cushing’s syndrome (CS) is a rare and severe disease caused by sustained hypercortisolism. The clinical manifestations of CS can be atypical in the elderly, and the diagnosis in these patients is often missed. Infectious Purpura Fulminans (PF) is a life-threating, thrombotic form of disseminated intravascular coagulation with high mortality. To our knowledge, PF occurring in a patient with CS has not been reported previously.

Methods

We described an 84-year-old female presented with severe infection, but normal temperature. She suffered from a variety of diseases especially personality change. Physical examination revealed thin skin, general edema, and multiple scattered ecchymosis. Combined with obviously elevated serum cortisol (36.85 ug/dl) and adenoma revealed by adrenal CT scanning, endogenous CS was diagnosed. During hospitalization, the patient developed serious subcutaneous hemorrhage on the right thigh and back. The skin biopsy showed multiple small vessel thrombosis suggesting that the patient developed the rare complication of CS, Purpura Fulminans (PF).

Results

Chronic hypercortisolism can cause immune suppression, low-grade inflammation, endothelial damage, and a hypercoagulable state, which together increased susceptibility of PF. Fluid resuscitation, antibiotics, infusion of blood product, and debridement were effective treatment measures when CS complicated with infectious PF.

Conclusion

Severe subcutaneous hemorrhage due to PF could occur in the patients of CS, especially in the elderly. Clinicians should be alert to the diagnosis of CS in older adults with cognitive decline and personality change.
Literature
1.
go back to reference J. Newell-Price, X. Bertagna, A.B. Grossman, L.K. Nieman, Cushing’s syndrome. Lancet 367, 1605–1617 (2006)CrossRef J. Newell-Price, X. Bertagna, A.B. Grossman, L.K. Nieman, Cushing’s syndrome. Lancet 367, 1605–1617 (2006)CrossRef
2.
go back to reference L.T. Braun, M. Reincke, What is the role of medical therapy in adrenal-dependent Cushing’s syndrome? Best. Pract. Res Clin. Endocrinol. Metab. 34, 101376 (2020)CrossRef L.T. Braun, M. Reincke, What is the role of medical therapy in adrenal-dependent Cushing’s syndrome? Best. Pract. Res Clin. Endocrinol. Metab. 34, 101376 (2020)CrossRef
3.
go back to reference P. Javanmard, D. Duan, E.B. Geer, Mortality in patients with endogenous Cushing’s syndrome. Endocrinol. Metab. Clin. N. Am. 47, 313–333 (2018)CrossRef P. Javanmard, D. Duan, E.B. Geer, Mortality in patients with endogenous Cushing’s syndrome. Endocrinol. Metab. Clin. N. Am. 47, 313–333 (2018)CrossRef
4.
go back to reference V. Hasenmajer, E. Sbardella, F. Sciarra, M. Minnetti, A.M. Isidori, M.A. Venneri, The immune system in Cushing’s syndrome. Trends Endocrinol. Metab. 31, 655–669 (2020)CrossRef V. Hasenmajer, E. Sbardella, F. Sciarra, M. Minnetti, A.M. Isidori, M.A. Venneri, The immune system in Cushing’s syndrome. Trends Endocrinol. Metab. 31, 655–669 (2020)CrossRef
5.
go back to reference M.E. Colling, P.K. Bendapudi, Purpura Fulminans: mechanism and management of dysregulated hemostasis. Transfus. Med. Rev. 32, 69–76 (2018)CrossRef M.E. Colling, P.K. Bendapudi, Purpura Fulminans: mechanism and management of dysregulated hemostasis. Transfus. Med. Rev. 32, 69–76 (2018)CrossRef
6.
go back to reference A. Lacroix, R.A. Feelders, C.A. Stratakis, L.K. Nieman, Cushing’s syndrome. Lancet 386, 913–927 (2015)CrossRef A. Lacroix, R.A. Feelders, C.A. Stratakis, L.K. Nieman, Cushing’s syndrome. Lancet 386, 913–927 (2015)CrossRef
7.
go back to reference L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)CrossRef L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)CrossRef
8.
go back to reference F. Ferraù, M. Korbonits. (eds.) Metabolic syndrome consequent to endocrine disorders. Front. Horm. Res. 49, 85–103 (2018) F. Ferraù, M. Korbonits. (eds.) Metabolic syndrome consequent to endocrine disorders. Front. Horm. Res. 49, 85–103 (2018)
9.
go back to reference C.A. Stratakis, Skin manifestations of Cushing’s syndrome. Rev. Endocr. Metab. Disord. 17, 283–286 (2016)CrossRef C.A. Stratakis, Skin manifestations of Cushing’s syndrome. Rev. Endocr. Metab. Disord. 17, 283–286 (2016)CrossRef
10.
go back to reference T. Kugai, H. Nakagawa, Evolution of Purpura Fulminans. N. Engl. J. Med. 376, 2182 (2017)CrossRef T. Kugai, H. Nakagawa, Evolution of Purpura Fulminans. N. Engl. J. Med. 376, 2182 (2017)CrossRef
Metadata
Title
Rare complication of cushing’s syndrome in the elderly: a case report
Authors
Cui Li
Guihua Cao
Fengzhong Jin
Xiaoxuan Ning
Publication date
01-11-2021
Publisher
Springer US
Published in
Endocrine / Issue 2/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02844-5

Other articles of this Issue 2/2021

Endocrine 2/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.